DEF 14A

Company

Viking Therapeutics, Inc.

Filed

April 5, 2024

Period of Report

May 21, 2024

Accession Number

0000950170-24-042251

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →